Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study-Reference-Cited by-同舟云学术

Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study

Published:2010-05 Issue:2 Volume:117 Page:324-329
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Rose Peter G.,Tian Chunqiao,Bookman Michael A.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference31 articles.

1. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population;Markman;J Clin Oncol,1992

2. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000

3. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer;ten Bokkel Huinink;J Clin Oncol,1997

4. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan;Gordon;J Clin Oncol,2001

5. Second-line treatment of ovarian cancer;Markman;Oncologist,2000

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer;Science Translational Medicine;2023-06-21

2. BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer;2022-12-04

3. Efficacy of non‑platinum chemotherapy in platinum‑resistant ovarian cancer: a meta‑analysis;Malignant tumours;2022-04-08

4. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework;Health Technology Assessment;2021-12

5. Docetaxel and carboplatin chemotherapy for treating patients with stage IVB or recurrent non-squamous cell carcinoma of the uterine cervix: a phase II study;International Journal of Clinical Oncology;2021-04-07